Fast-acting insulin aspart (faster aspart) is a novel formulation of insulin aspart (IAsp) containing the additional excipients niacinamide and L‐arginine. The improved pharmacological profile and greater early glucose-lowering action of faster aspart compared with IAsp suggests that faster aspart may be advantageous for people with diabetes using continuous subcutaneous insulin infusion (CSII). The recent onset 5 trial was the first to evaluate the efficacy and safety of an ultra-fast-acting insulin in CSII therapy in a large number of participants with type 1 diabetes (T1D). Faster aspart was confirmed to be non-inferior to IAsp in terms of HbA1c reduction and demonstrated significantly improved postprandial glucose control after a standardized meal test without an increased risk of overall severe or blood glucose-confirmed hypoglycaemia. This review summarizes the available clinical evidence for faster aspart administered via CSII and highlights practical considerations based on clinical experience that may help healthcare providers and people with T1D successfully initiate and adjust faster aspart in CSII.